THURSDAY, July 17, 2025 (HealthDay News) — A new antibody shot that protects babies against RSV infection could be struggling to gain traction, researchers report. Only about a third (35%) of babies eligible for nirsevimab got the injection during the 2023-24 RSV season, researchers reported today in the journal Pediatrics.Continue Reading